Blog Tag
5 articles tagged with Biotech Data. The newest post is from Feb 23, 2026.
A biomarker is a measurable biological indicator used to understand disease, track response, or help guide treatment. In biotech, biomarkers can be found in blood, tissue, imaging, genetics, or other testable signals. They matter because they can help researchers and investors understand whether a drug is hitting its target or whether a patient population is likely to benefit.
A secondary endpoint is an additional outcome a clinical trial measures beyond the primary endpoint. It can help support the main finding, add clinical context, or provide more detailed information about the drug’s effect. In biotech, secondary endpoints matter because they help investors understand whether the result is broad, durable, and clinically meaningful.
A primary endpoint is the main outcome a clinical trial is designed to measure. It is the most important endpoint in the study because it is the one the trial is formally powered and analyzed around. In biotech, whether the primary endpoint is met is often the first question investors ask when data is released.
A clinical trial endpoint is the specific outcome a study is designed to measure. In biotech, endpoints are central to how investors, regulators, clinicians, and companies interpret trial data because they define what success actually means. Without a clearly defined endpoint, it is impossible to know whether a trial achieved its goal.
A clinical trial readout is the public release of data from a clinical study. In biotech, the phrase usually refers to the first meaningful disclosure of results from a Phase 1, Phase 2, or Phase 3 trial. That readout may come as a company press release, a conference presentation, an abstract, an SEC filing, or a combination of sources. Regardless of format, the readout is one of the most important events in biotech because it converts scientific work into public evidence.
